The American Brachytherapy Society (ABS) Gynecologic Cervical Cancer Task group has developed general criteria for the management of cervical cancer, designed to guide Radiation Oncologists and assist in making decisions regarding therapy. The complexity and severity of a patient’s clinical condition should dictate the selection of appropriate treatment, but the availability of equipment and/or personnel may also influence the choice of therapy. Approaches classified as investigational by the U.S. Food and Drug Administration (FDA) have not been considered in developing these criteria. The ultimate decision regarding the appropriateness of any treatment must be made by the attending physician. Highlights of the ABS recommendations are given below.

Gynecologic Brachytherapy:
The radiation dose delivered by brachytherapy is critical in curing patients of cervical cancer and has been the standard of treatment for over 100 years.

General Inclusion Criteria:
- Inoperable Stage IA1 and IA2 cervical cancer patients may be treated definitively with tandem-based brachytherapy alone.
- Inoperable Stage IB1 cervical cancer patients should be treated radically with brachytherapy in conjunction with external beam radiation. Concurrent chemotherapy may be considered at the physician’s discretion and based on the presence of high risk features.
- Clinical stage IB2 - IVA Cervical Cancer should be treated radically with concurrent chemoradiation followed by brachytherapy.
- Stage IVB cervical cancer may be palliatively treated with brachytherapy with or without external beam to decrease the risk of severe hemorrhage or other life-threatening symptoms.
- Patients are treated with brachytherapy regardless of lymph node status, grade, presence of lymphovascular invasion, tumor size, age, or histology. Rarely, medical comorbidities may prohibit brachytherapy.
- The use of Intensity-Modulated Radiation Therapy (IMRT) or 3D conformal external beam radiation is not a substitute for brachytherapy.

Exclusion Criteria: Absolute contraindications to radical treatment
- Prior pelvic radiotherapy with brachytherapy
- Life expectancy < 6 months

Intraoperative Procedure:
- Standard brachytherapy procedure consists of dilating the cervical os, with ultrasound guidance to assist with tandem placement for difficult cases including cervix erosion, flattening, or cases where the os is not visible.
- Radiographic, CT, or MRI imaging to assist with dose prescription.
• Tandem and ovoid, tandem and ring or tandem and cylinders for intracavitary applications, inserted free hand
• Hollow interstitial needles inserted either freehand or with template or ultrasound guidance (e.g., template or guide holes in a ring applicator) for interstitial applications

Source Delivery System:
• HDR remote afterloader using iridium-192 in an outpatient setting
• PDR remote afterloader using iridium-192 in an inpatient setting
• LDR manually loaded or remote afterloader using cesium-137 and/or iridium-192 in an inpatient setting

Treatment Planning:
Dosimetry should be performed every time applicators are inserted to assess doses to the targets as well as the normal tissues, even if fixed geometry applicators are used. Failure to perform dosimetry can result in exceeding the normal tissue tolerance of the organs at risk.

• Planning target volume:
  • Point A should be reported for all cases regardless of the imaging modality utilized.
  • For institutions that utilize MRI, GTV for the cervix, high-risk CTV of the cervix plus tumor extension at the time of brachytherapy, intermediate-risk CTV of the cervix plus tumor extension at the time of diagnosis as defined by the GEC-ESTRO recommendations. Point A must always be reported, as should the D90, V100 and D2cc to the rectum, bladder and sigmoid.
  • For institutions that utilize CT, the width of the cervix and any parametrial extension should be contoured (HR-CTV-CT). The superior border of the cervix should extend at least 1cm above either the uterine vessels identified by IV contrast, or the location where the uterus begins to enlarge. If these cannot be identified, a height of 3cm should be contoured for the cervix.
  • Delineation of target volumes to be performed after insertion of tandem and vaginal applicators or interstitial applicator on images in the treatment planning computer.
  • Treatment planning for intracavitary applications should be performed after brachytherapy insertion and prior to treatment.
  • A pre-implant scan before the procedure may be performed for interstitial cases to assist with proper catheter placement.
  • Image-based volumetric information shall consist of CT, or MRI using contiguous slice acquisition with slice thicknesses ≤3 mm
  • Organs at risk to be contoured (including bladder, rectum, and sigmoid) are defined at the time of brachytherapy.
  • DVH information is used for assessment of coverage of the target and dose to organs at risk.
  • Reporting: Standard parameters reported in the GEC-ESTRO recommendations include the D2cc for the organs at risk; D90 and V100 for tumor.
• **Dosimetry**
  • Recommended prescription dosimetric parameters that should be met or exceeded.
  • Target coverage D90 should equal 100% of prescription
  • D2cc to the sigmoid <75 Gy and D2cc to the rectum <75 Gy. No bladder parameter is currently defined. A D2cc <95 Gy has been reported.
  • **Dose homogeneity:**
    • The importance of dose homogeneity is unclear.
    • Efforts should be made to spare the bladder, rectum, and sigmoid.

**Recommended Prescription:**
• Low-dose-rate prescription may be in milligram-hours or in cGy to Point A or LDR primary treatment of 45-50 Gy external-beam plus 40-60 cGy/hr to a cumulative dose of 40-45 Gy.
• Goal TD should be >85 Gy. High-dose-rate typically prescribed in one of the following fractionation regimes: 5.5 Gy x 5, 6 Gy x 5, 7 Gy x 4

**Timing**
• All treatment, including external-beam and brachytherapy, must be completed within 56 days from initiation of treatment.
• High-dose-rate brachytherapy commences after 39.6 Gy or 45 Gy with up to 2 fractions being given per week during the conclusion of external beam and during the parametral boost portion of treatment. Brachytherapy may be initiated earlier, but no earlier than approximately 20 Gy, if the physician determines that the applicator placed at this time point would provide adequate tumor coverage and sparing of normal tissues. Alternatively, if 45 Gy is delivered to the whole pelvis prior to brachytherapy, two brachytherapy insertions per week should be given to avoid treatment prolongation.
• Low-dose-rate implants commence after external beam treatment is completed with one implant per week.
• Chemotherapy is not typically given on the days of HDR brachytherapy but may be given with LDR brachytherapy

**Post-Treatment Evaluation:**
• Cervical cancer patients typically have Pap smear follow-ups every 3 months for 2 years, every 6 months for 3 years thereafter, then yearly.
• PET evaluation at 3 months has shown to be prognostic. The use of PET imaging at time points other than 3 months should be considered on an individual basis.
• Physical examination for recurrence or complications is necessary.
• Quality of life and patient satisfaction should be considered.
• Post-treatment biopsy may be needed to rule out recurrence.
SELECTED READING

I. PRACTICE PATTERNS


HDR versus LDR

II. TREATMENT PLANNING

A. Standard 2D


B. 3-D Image Guided Brachytherapy


1. Contouring MR images with brachytherapy applicator in place:


2. Treatment Planning with MR images:


3. CT or US based treatment planning:


S Van Dyk, D Bernshaw, Ultrasound-based conformal planning for Gynaecological Brachytherapy, Journal of Medical Imaging and Radiation Oncology. 2008; 52 (1) :77–84


4. Clinical outcome with 3D based planning for cervical cancer


II. Diagnostic Imaging


III. Applicator Selection


IV. RADIOBIOLOGY

V. IMAGING QA


VI. MORBIDITY


Georg P, Dimopoulos J, Kirisits C, Lang S, Berger D, Pötter R. The Predictive Value of Dose Volume Parameters in MRI Based Cervical Cancer Brachytherapy for Late

